Related Experiment Videos
Effective targeted cytotoxicity of neuroblastoma cells
Patrick B Thomas1, Stephen J Delatte, Aimee Sutphin
1Division of Pediatric Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC, USA.
Background/Purpose:
Despite aggressive treatment with surgery, chemotherapy, and radiotherapy, the prognosis for many children with neuroblastoma remains poor. Targeted toxins represent novel cancer therapeutics designed to selectively target and kill cancer cells. The authors have developed a novel fusion toxin, DT5F11, consisting of truncated diphtheria toxin (DT(A)) linked to a single chain antibody (sc5F11) targeting the GD(2) antigen found on most neuroblastoma cells. This report describes the construction, expression, and in vitro function of DT5F11.
Methods:
Utilizing restriction enzyme digestion, polymerase chain reaction amplification, and gel electrophoresis, the prkDTL5F11 plasmid was created by the fusion of distinct coding sequences for a single-chain GD(2) targeting antibody (sc5F11) and truncated diphtheria toxin (DT(A)). DH5alpha Escherichi coli-competent cells were transformed with prkDTL5F11; DNA was amplified, isolated, and sequenced. The fusion protein was expressed and assayed by Western blot. Targeted cytotoxicity was analyzed on GD(2)-positive (SK-N-AS, IMR-32, SK-N-MC, LAN-1) and GD(2)-negative (HeLa) cells.
Results:
Fluorescent dye-labeled cycle sequencing identified the constructed fusion toxin gene. Western blot analysis using a mouse antihuman DT(A) antibody showed a 69-kD band identifying the fusion toxin, DT5F11. Targeted cell killing with DT5F11 was seen only in GD(2) positive cells.
Conclusions:
This study demonstrates creation of a novel fusion toxin with effective GD(2)-targeted cellular toxicity. Further investigation of this fusion toxin as a therapeutic agent in the management of neuroblastoma is warranted.
Insights
A novel fusion toxin, DT5F11, effectively targets and kills GD(2)-positive neuroblastoma cells. This targeted therapy shows promise for improving outcomes in pediatric neuroblastoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Neuroblastoma prognosis remains poor despite aggressive treatments.
- Targeted toxins offer a novel therapeutic approach for cancer.
- GD(2) antigen is present on most neuroblastoma cells.
Purpose of the Study:
- To construct and characterize a novel fusion toxin, DT5F11.
- To evaluate the in vitro function and targeted cytotoxicity of DT5F11.
- To assess the potential of DT5F11 as a therapeutic agent for neuroblastoma.
Main Methods:
- Created the prkDTL5F11 plasmid by fusing DT(A) and sc5F11 genes.
- Amplified, isolated, and sequenced the fusion toxin gene.
- Assayed fusion protein expression via Western blot and tested cytotoxicity on GD(2)-positive and negative cells.
Main Results:
- Successfully constructed and identified the DT5F11 fusion toxin gene.
- Western blot confirmed the expression of the 69-kD DT5F11 fusion protein.
- DT5F11 demonstrated targeted cellular toxicity exclusively in GD(2)-positive neuroblastoma cells.
Conclusions:
- DT5F11 is a novel fusion toxin with potent GD(2)-targeted cellular toxicity.
- This fusion toxin holds potential as a therapeutic agent for neuroblastoma.
- Further research is warranted to explore DT5F11 in neuroblastoma management.